SGLT-2 INHIBITION ADDED TO GLP-1 AGONIST THERAPY FOR TYPE 2 DIABETES: WHAT IS THE BENEFIT?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Endocrine Practice

• Publication date

  2015-12-07

• Fields of study

  Medicine

• Identifiers
  DOI 10.4158/EP151013.COPMID 26484408
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Sodium‐glucose cotransporter 2 inhibitor‐associated diabetic ketoacidosis: Report of two cases with hyperglycemic ketoacidosis in type 1 diabetes

  2016cited by this paper
• Combination of Empagliflozin and Linagliptin as Second-Line Therapy in Subjects With Type 2 Diabetes Inadequately Controlled on Metformin

  2015cited by this paper
• Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition

  2015cited by this paper
• Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.

  2015cited by this paper
• Possible adverse effects of SGLT2 inhibitors on bone.

  2015cited by this paper
• Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion

  2015cited by this paper
• Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis

  2015cited by this paper
• The Impact of Chronic Liraglutide Therapy on Glucagon Secretion in Type 2 Diabetes: Insight From the LIBRA Trial.

  2015cited by this paper
• SGLT inhibition and euglycaemic diabetic ketoacidosis.

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Randomized, Double-Blind, Phase 3 Trial of Triple Therapy With Dapagliflozin Add-on to Saxagliptin Plus Metformin in Type 2 Diabetes

  2015cited by this paper
• SGLT-2 INHIBITOR THERAPY ADDED TO GLP-1 AGONIST THERAPY IN THE MANAGEMENT OF T2DM.

  2015cited by this paper
• Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies

  2014cited by this paper
• Postprandial dynamics of plasma glucose, insulin, and glucagon in patients with type 2 diabetes treated with saxagliptin plus dapagliflozin add-on to metformin therapy.

  2014cited by this paper
• Dapagliflozin Is Effective as Add-on Therapy to Sitagliptin With or Without Metformin: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study

  2014cited by this paper
• Healthcare outcomes assessed with observational study designs compared with those assessed in randomized trials.

  2014cited by this paper
• Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?

  2014cited by this paper
• Bias in observational study designs: prospective cohort studies

  2014cited by this paper
• Quality standards for real-world research. Focus on observational database studies of comparative effectiveness.

  2014cited by this paper
• Observational studies: going beyond the boundaries of randomized controlled trials.

  2010cited by this paper
• Overview of the Epidemiology Methods and Applications: Strengths and Limitations of Observational Study Designs

  2010cited by this paper
• Bias: considerations for research practice.

  2008cited by this paper

• No citing papers are available for this paper.